Reuters logo
BRIEF-FDA accepts Lundbeck drug labeling for review
April 30, 2014 / 1:16 PM / 3 years ago

BRIEF-FDA accepts Lundbeck drug labeling for review

COPENHAGEN, April 30 (Reuters) - Danish pharmaceutical company Lundbeck said on Wednesday: * United States’ Food and Drug Administration has accepted for review a supplemental new drug application (SNDA) for the proposed expanded labeling of schizophrenia drug Abilify Maintena, which is developed by Otsuka Pharmaceutical and Lundbeck. Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below